Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 19/20 | 0.61 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.61 |
| ▸ | ITGB6 | P18564 | 5/20 | 0.61 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.61 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.52 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4394930 | 1.00 | ITGAV (0.61) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL4405860 | 0.98 | ITGAV (0.65) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL4399319 | 0.98 | ITGAV (0.65) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL4394834 | 0.95 | ITGAV (0.67) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL4399092 | 0.95 | ITGAV (0.67) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL4394830 | 0.95 | ITGAV (0.67) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL4402354 | 0.94 | ITGAV (0.61) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| Trifluoroacetic Acid SCHEMBL4393233 | 0.94 | ITGAV (0.61) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL4399824 | 0.92 | ITGB3 (0.71) | ITGAVITGB3ITGA2BITGB6ITGB5 | |
| SCHEMBL4404814 | 0.92 | ITGB3 (0.71) | ITGAVITGB3ITGA2BITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632951-B2 | Inhibitors of integrin ανβ6 | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2009-12-15 | — | — | US | disclosed |
| EP-1377540-B1 | INHIBITORS OF INTEGRIN ALPHA-V-BETA-6 | MERCK PATENT GMBH (DE) | 2008-12-03 | — | — | EP | disclosed |
| US-20040092454-A1 | Inhibitors of integrin alphavbeta6 | MERCK PATENT GMBH (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-1377540-A1 | INHIBITORS OF INTEGRIN AvB6 | MERCK PATENT GmbH (DE) | 2004-01-07 | — | — | EP | disclosed |
| WO-2002074730-A1 | INHIBITORS OF INTEGRIN αvβ¿6? | MERCK PATENT GMBH (DE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092454-A1 | Inhibitors of integrin alphavbeta6 | ITGB6, ITGB1, ITGA1 | ITGAV 7/4885ITGB3 8/4885ITGA2B 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.